IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2016/09/01
-
Journal
-
Indian UGC (journal)
-
Citations5
-
Stephane de Botton
-
Johanna Mondesir
-
Christophe Willekens
-
Mehdi Touat
Cite
de Botton, Stephane, et al. “IDH1 and IDH2 Mutations As Novel Therapeutic Targets: Current Perspectives”. Journal of Blood Medicine, vol. Volume 7, 2016, pp. 171-80, https://doi.org/10.2147/jbm.s70716.
de Botton, S., Mondesir, J., Willekens, C., & Touat, M. (2016). IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. Journal of Blood Medicine, Volume 7, 171-180. https://doi.org/10.2147/jbm.s70716
de Botton, Stephane, Johanna Mondesir, Christophe Willekens, and Mehdi Touat. “IDH1 and IDH2 Mutations As Novel Therapeutic Targets: Current Perspectives”. Journal of Blood Medicine Volume 7 (2016): 171-80. https://doi.org/10.2147/jbm.s70716.
de Botton S, Mondesir J, Willekens C, Touat M. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. Journal of Blood Medicine. 2016;Volume 7:171-80.
Journal Category
Medicine
Internal medicine
Specialties of internal medicine
Diseases of the blood and blood-forming organs
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Fetal de novo heterozygous variant in the isocitrate dehydrogenase 1 gene associated with growth restriction, skeletal, cerebral and vascular anomalies | Prenatal Diagnosis |
| 2023 | |
Update for astrocytomas: medical and surgical management considerations | 2 | 2023 | ||
Targeted Therapies for Perihilar Cholangiocarcinoma | Cancers |
| 6 | 2022 |
Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Glioma—A Case Report and Systematic Review | Current Issues in Molecular Biology |
| 4 | 2022 |
Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma | Biomolecules |
| 3 | 2020 |
Citations Analysis
The category
Science: Biology (General): Genetics 2
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma and was published in 2020. The most recent citation comes from a 2023 study titled Fetal de novo heterozygous variant in the isocitrate dehydrogenase 1 gene associated with growth restriction, skeletal, cerebral and vascular anomalies. This article reached its peak citation in 2023, with 2 citations. It has been cited in 4 different journals, 50% of which are open access. Among related journals, the Prenatal Diagnosis cited this research the most, with 1 citations. The chart below illustrates the annual citation trends for this article.